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AbstrACt
Introduction While early psychosis intervention 
(EPI) has proliferated in recent years amid evidence 
of its effectiveness, programmes often struggle to 
deliver consistent, recovery- based care. NAVIGATE is a 
manualised model of EPI with demonstrated effectiveness 
consisting of four components: individualised medication 
management, individual resiliency training, supported 
employment and education and family education. 
We aim to implement NAVIGATE in geographically 
diverse EPI programmes in Ontario, Canada, evaluating 
implementation and its effect on idelity to the EPI model, 
as well as individual- level outcomes (patient/family 
member- reported and interviewer- rated), system- level 
outcomes (captured in provincial administrative databases) 
and engagement of participants with lived experience.
Methods and analysis This is a multisite, non- 
randomised pragmatic hybrid effectiveness- 
implementation type III mixed methods study coordinated 
at the Centre for Addiction and Mental Health (CAMH) in 
Toronto. Implementation is supported by the Provincial 
System Support Program, a CAMH- based programme 
with provincial ofices across Ontario, and Extension of 
Community Healthcare Outcomes Ontario Mental Health at 
CAMH and the University of Toronto. The primary outcome 
is idelity to the EPI model as measured using the First 
Episode Psychosis Services—Fidelity Scale. Four hundred 
participants in the EPI programmes will be recruited and 
followed using both individual- level assessments and 
health administrative data for 2 years following NAVIGATE 
initiation. People with lived experience will be engaged 
in all aspects of the project, including through youth and 
family advisory committees.
Ethics and dissemination Research ethics board 
approval has been obtained from CAMH and institutions 
overseeing the local EPI programmes. Study indings 
will be reported in scientiic journal articles and shared 
with key stakeholders including youth, family members, 
programme staff and policymakers.
trial registration number NCT03919760; Pre-results.
IntroduCtIon
Psychosis typically has its onset in youth and 
emerging adults (YEAs), a critical devel-
opmental stage for exploring and solidi-
fying future career trajectories, intimate 
strengths and limitations of this study
 Ź Real- world design leveraging routinely collected ad-
ministrative data, established network of early psy-
chosis intervention programmes and routine idelity 
assessments.
 Ź Implementation supported by regional specialists 
and Project Extension of Community Healthcare 
Outcomes, a digitally supported hub- and- spoke 
training model.
 Ź Collaboration with youth, family members and other 
stakeholders including government policymakers at 
all stages of the project.
 Ź Interpretation of indings limited by absence of a 
comparison group for individual- level (patient/family 
member- reported and interviewer- rated) outcomes.
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relationships and worldviews.1–3 Psychosis is a group of 
symptoms characteristic of diagnoses of schizophrenia, 
schizoaffective disorder, substance- induced psychotic 
disorders and bipolar disorder or major depressive 
disorder with psychotic features; taken together, these 
disorders account for the greatest disability among 
all medical illnesses in YEAs in developed countries.4 
Furthermore, these conditions account for high health-
care costs.5 They can have a profound effect on young 
people: evidence suggests that a recent diagnosis of 
psychotic disorder confers an 8–24- fold greater mortality 
rate among YEAs compared with the general popula-
tion, mostly due to suicide.6 7 Even after accounting for 
suicide, people with these disorders experience a short-
ened lifespan attributable to downward socioeconomic 
drift and poorly treated comorbid physical health disor-
ders.8–10 Consistent evidence has demonstrated that 
longer duration of untreated psychosis is associated with 
more severe symptoms, lower likelihood of remission, 
poor social functioning and global outcome.11
Early psychosis intervention (EPI) programmes are 
designed to reduce barriers to treatment and improve 
recovery from first- episode psychosis (FEP). In a natural-
istic study in Ontario, receiving care in an EPI programme 
was associated with improved access to psychiatric care, 
fewer emergency department (ED) visits and reduced all- 
cause mortality.12 Additional benefits associated with EPI 
in the literature include improved psychosis symptoms 
and reduced risk of relapse, fewer hospital readmissions 
and increased employment rates.13–16 Evidence suggests 
that EPI is likely cost effective, and possibly even cost 
saving compared with alternatives.17 Despite the demon-
strated benefits of EPI, disability associated with psychotic 
disorders has not improved,18 and recovery rates in EPI 
programmes remain low.19 Achieving consistent delivery 
of high- quality, evidence- based care in EPI programmes 
is a major challenge.20 This may be related to specific 
deficits in delivering recovery- based services, including 
case management coupled with individualised psycho-
social interventions, family education and support, and 
supported education and employment. Even in clinical 
service delivery trials, only a minority of patients receive 
the full range of psychosocial interventions offered by the 
service.13 14 Effective implementation and sustainability of 
recovery- based care in real- world EPI settings remains a 
challenge.21–24
The province of Ontario, Canada has prioritised EPI 
care through a separate funding stream and the estab-
lishment of EPI programme standards,25 with over 50 
EPI sites delivering care for both non- affective and affec-
tive psychosis (ie, bipolar disorder and major depressive 
disorder with psychotic features). These EPI programmes 
are coordinated through the Early Psychosis Intervention 
Ontario Network (EPION), which receives funding from 
the Ministry of Health and operational, professional and 
financial management support from the Provincial System 
Support Program (PSSP), based at the Centre for Addic-
tion and Mental Health (CAMH) in Toronto. EPION and 
PSSP led a pilot study to measure fidelity to current EPI 
standards using the First Episode Psychosis Services—
Fidelity Scale (FEPS- FS)26 completed by peer assessors.27 
The study found that the assessed EPI programmes 
lacked a structured or manualised process for delivering 
recovery- oriented care, which aligned with a prior key 
informant survey in which Ontario EPI programmes cited 
a need for tools to support service delivery, access to staff 
training and guidance on implementing new practices.22 
Despite being connected by EPION, these programmes 
felt they were lacking a community of practice.
NAVIGATE was developed and studied with funding 
from the National Institute of Mental Health Recovery 
After an Initial Schizophrenia Episode (RAISE) Initiative. 
A model that addresses the need for consistently deliv-
ered recovery- based services, NAVIGATE is a form of 
coordinated specialty care for FEP consisting of four key 
intervention components: (1) individualised medication 
management using a decision support tool, (2) a package 
of psychoeducation and a blend of evidence- based 
psychotherapies called ‘individual resiliency training’, (3) 
supported employment and education and (4) a family 
education programme.28 NAVIGATE operationalises 
current EPI standards using manualised protocols, and 
systematically applies the four components to all patients. 
Regular team reviews assess patient progress, fidelity and 
need for adjustments. NAVIGATE was evaluated from 
2009 to 2014 in a cluster randomised controlled trial 
(RCT) involving 404 individuals with FEP in 34 commu-
nity mental health centres across the USA with no pre- 
existing EPI programmes.21 Compared with usual care, 
NAVIGATE treatment provided greater improvement in 
symptoms and real- world functioning, including social 
functioning and engagement in educational and voca-
tional training.21 29
CAMH, having implemented NAVIGATE in its EPI 
programme, partnered with PSSP, EPION, the Ontario 
Ministry of Health and former EPI service users on a Cana-
dian Institutes of Health Research Strategy for Patient- 
Oriented Research Innovative Clinical Trials grant to 
evaluate implementation of NAVIGATE in diverse EPI 
sites across the province. Implementation support is 
provided by PSSP. Training is delivered by experts who 
developed the NAVIGATE model, as well as expert users 
from CAMH. Knowledge transfer is supported by the 
Extension of Community Healthcare Outcomes (ECHO) 
Ontario Mental Health at CAMH and the University of 
Toronto, which consists of specialist hubs connected with 
multiple spoke (learner) teams in remote areas through 
secure multipoint videoconferencing technology. ECHO 
is designed to facilitate an interprofessional community 
of practice, provide access to specialised expertise and 
overcome geographic barriers in relation to coordinated 
specialty care. It has evidence of clinical effectiveness 
in the USA,30 and high provider satisfaction, increased 
knowledge and self- efficacy in managing mental health 
and addictions in rural and remote settings in Ontario.31 
This implementation plan prioritises affordability, 
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adaptability, spread and sustainability, as well as patient 
and caregiver engagement. In addition to collecting 
individual- level data, the study will examine outcomes 
with relevant comparison groups in administrative data 
held at Institute for Clinical Evaluative Sciences (ICES) 
at dramatically lower time and cost compared with an 
RCT.
objectives
Early Psychosis Intervention- Spreading Evidence- based 
Treatment (EPI- SET), a multisite non- randomised 
effectiveness- implementation hybrid type III trial,32 will 
evaluate the implementation and impact of NAVIGATE 
in five EPI programmes in Ontario, supported by PSSP’s 
provincial regional network of implementation experts, 
and training through ECHO. First, we will assess at a 
programme level whether implementation of NAVI-
GATE, as a structured model of care, leads to improved 
fidelity to the EPI standard. Because NAVIGATE has not 
been evaluated in Ontario, which, unlike the original 
RAISE Study setting in the USA, is characterised by estab-
lished EPI programmes and a system of universal health-
care, we will also assess the effectiveness of NAVIGATE 
in improving individual- level outcomes over time, and 
system- level outcomes using quasi- experimental methods 
and administrative data. Lastly, we will measure youth and 
family member engagement in the study. Specifically, our 
primary objectives are to:
 Ź Assess implementation of NAVIGATE and whether 
this leads to improvement in fidelity to the EPI stand-
ards (using the FEPS- FS).26
 Ź Determine longitudinal change in functioning and 
symptoms in NAVIGATE patients.
 Ź Compare system- level outcomes, including days in 
hospital, ED visits, suicide attempts, mortality and 
system costs among patients receiving NAVIGATE 
compared with patients at other EPI sites not receiving 
NAVIGATE as well as patients with psychotic disorders 
who are not enrolled in EPI.
 Ź Evaluate youth and family member engagement in 
this implementation study according to established 
frameworks.
MEthods And AnAlysIs
study setting
Ontario is the most populous province in Canada, with 
a population of approximately 14 million and a system 
of universal healthcare delivered through the Ontario 
Health Insurance Plan (OHIP). Five EPI programmes 
have been selected to represent different geographic 
regions of Ontario. Each site offers services from a psychi-
atrist as well as other health professionals (nurses, occu-
pational therapists and social workers) who provide case 
management and family support. The diversity of sites 
allows for the opportunity to examine subpopulations, 
including ethno- racial minority groups, Indigenous 
populations and rural residents. CAMH acts as the coor-
dinating site.
Eligibility criteria
Mirroring the RAISE Study, we will recruit 400 patients 
(100 in months 6–12, 300 in months 12–24) into the study 
with a 2- year follow- up.33 Participants will be in their first 
year of treatment in the participating EPI programmes. 
Inclusion criteria are broad, reflecting the real- world 
populations served by the programmes.
Inclusion criteria
 Ź Age range of 14–35 years.
 Ź Any Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) diagnosis that can manifest as 
FEP (schizophrenia, schizoaffective disorder, schizo-
phreniform disorder, bipolar I disorder with psychotic 
features, major depressive disorder with psychotic 
features, substance- induced psychotic disorder or 
unspecified psychotic disorder).
 Ź Within first year of treatment at a participating EPI 
programme.
Exclusion criteria
 Ź Absence of psychosis.
 Ź Inability to provide informed consent to participate in 
the research study.
objECtIvE 1: IMplEMEntAtIon And EvAluAtIon
Implementation plan
Participating EPI programmes are guided through a 
facilitated, staged, change process.34 35 Regional PSSP 
facilitators lead implementation in collaboration with 
NAVIGATE trainers, CAMH NAVIGATE experts and 
the EPI programme staff lead at each site.36 ECHO will 
become increasingly involved over time to support NAVI-
GATE as part of routine practice, and this will also be 
monitored. The stages of our implementation process are 
summarised in table 1.
Implementation evaluation
The implementation evaluation is summarised in table 2.37 
Fidelity to the EPI standard, our primary outcome, will 
be assessed using the FEPS- FS.26 The FEPS- FS is a vali-
dated measure of fidelity of service delivery to the current 
standard of EPI evidence- based practice based on 32 
program- specific items (individual and team practices) 
rated on a 5- point scale from ‘not implemented’ to ‘fully 
implemented’. A rating of 4 is considered satisfactory 
adherence. Trained assessors will review site adminis-
trative data, data abstracted from client health records 
and conduct phone interviews with site staff to complete 
the FEPS- FS. Fidelity assessments will be conducted for 
each site at baseline, 1 year and 2 years post implemen-
tation. Descriptive statistics (percentages, means and 
ranges) will be reported for the total scale score and for 
subscale scores that align with NAVIGATE components. 
With a small number of sites, we cannot quantitatively test 
changes over time and across sites but will describe and 
qualitatively compare findings.
To determine whether implementation of NAVIGATE 
is associated with improvement in fidelity to the EPI 
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Table 1 Stages of implementation to be used in EPI- SET
Stage Overarching goal Steps
1. Exploration To assess site capacity and 
need, build engagement
 Ź CAMH NAVIGATE experts, PSSP implementation specialists and ECHO team meet with 
each site to explain NAVIGATE, learn about their current stafing and service delivery 
processes and discuss how to integrate NAVIGATE into their practice.
 Ź EPI staff complete a site readiness assessment survey and a programme idelity review is 
conducted to learn more about site capacities and needs for NAVIGATE implementation.
2. Installation To create structures 
and build capacity for 
implementation
 Ź EPI staff and PSSP facilitators meet for an intensive in- person and/or blended in- person 
and virtual staff training over several days co- led by CAMH NAVIGATE experts and 
NAVIGATE trainers along with youth and family partners, delivered in lectures, role playing 
and discussions.
 Ź PSSP supports preparation, including staff allocation to each NAVIGATE role, how 
interventions will be documented, how documentation will be used in NAVIGATE 
supervision and how to prepare for ECHO sessions.
 Ź The ECHO team works with each site to ensure setup and ongoing functioning of 
infrastructure for live videoconferencing.
3. Initial 
implementation
To trial and reine 
implementation
 Ź Each site will begin NAVIGATE delivery using feedback from various sources, including 
ECHO training and coaching, contact and progress notes, and staff meetings to reine the 
implementation and service delivery processes and to build staff skills.
 Ź The PSSP implementation specialists will document progress, strategies and challenges 
to implementation in a structured log that they will share in regular meetings with the 
NAVIGATE experts and other facilitators for continuous improvement, mindful of site- 
speciic factors and population- speciic factors (eg, sex, race/ethnicity, rural vs urban) that 
may inluence implementation.
 Ź Staff feedback will be used to reine the implementation process.
4. Full 
implementation 
and sustainability
To stabilise practice so that 
the implemented practice 
is routine
 Ź NAVIGATE is fully embedded into the organisation and can be sustained with internal 
resources.
 Ź The ECHO team will work in collaboration with Study sites via videoconferencing 
technology to create and sustain a community of practice for NAVIGATE implementation 
and spread beyond the duration of this study, such that it becomes routine practice.
 Ź After each ECHO session, questionnaires will be used to evaluate satisfaction and 
inform ECHO modiications, and cases discussed during the sessions will generate 
implementation recommendations, with surveys approximately 3 months later to evaluate 
adherence to these recommendations.
 Ź Pre- knowledge and post- knowledge tests and competence assessments will be used to 
assess how knowledge changes throughout the ECHO cycle.
CAMH, Centre for Addiction and Mental Health; ECHO, Extension of Community Healthcare Outcomes; EPI, early psychosis intervention; EPION, 
Early Psychosis Intervention Ontario Network; EPI- SET, Early Psychosis Intervention- Spreading Evidence- based Treatment; PSSP, Provincial System 
Support Program.
standard, programme staff will document delivery of core 
modules for each of the four interventions. We will calcu-
late the percentage of core modules completed per inter-
vention per patient to assess penetration and to identify 
variations in delivery both within sites and across sites. 
Additionally, we will calculate frequency of team activities 
(eg, weekly meetings, direct supervision) and assess staff 
perceived competence in delivery of NAVIGATE using 
the readiness monitoring tool38 and the competency 
assessment questionnaires completed at the conclusion 
of each ECHO cycle (see below).
The consolidated framework for implementation 
research (CFIR)39 40 will be used to systematically assess 
contextual factors that are associated with effective imple-
mentation in relation to five major domains: interven-
tion characteristics (eg, complexity, relative advantage), 
outer setting (eg, external policy, patient needs), inner 
setting (eg, resources, fit, leadership), staff characteris-
tics (eg, knowledge, beliefs) and implementation process 
(eg, facilitation, planning, coaching). A semi- structured 
interview will guide data collection.39 41 Interviews will 
be conducted with EPI staff and organisation leaders at 
each site at the end of the active implementation and 
will be recorded and transcribed. The CFIR will provide 
the organising framework for qualitative data coding and 
analysis. At each analysis stage, coding and development 
of emergent themes will be conducted by multiple coders 
using NVivo software, with consensus achieved through 
discussion and deliberation. In combination with fidelity 
results, we will examine implementation facilitators and 
challenges within and across sites.
Following an established evaluation framework devel-
oped by ECHO that builds on continuing education 
programme evaluation,42–44 we will assess staff partici-
pation and retention, satisfaction with ECHO support 
and perceived changes in competence to deliver NAVI-
GATE. Competency assessment questionnaires will be 
administered to staff prior to participation in ECHO 
sessions and at the conclusion of each ECHO cycle to 
assess changes in attitudes, knowledge and self- efficacy 
(self- reported competence) in delivering NAVIGATE 
components.31
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Table 2 Implementation evaluation measures and timeline
Measurement domain Measure
Implementation stage
Explore (stage 1) Install (stage 2)
Initial 
implementation 
(stage 3)
Full implementation and 
sustainability
(stage 4)
Capacity 
and needs 
assessment
Plan and 
prepare Trial and refine
Stabilise 
practice
Practice is 
routine
Months
1–3
Months
4–6
Months
7–12
Months
13–24 Months 25–42
Implementation process
  Implementation 
milestones, risk, action
Tracker tool based on 
NIRN framework90
t t t t t
  ECHO implementation 
(clinical coaching)
Post- session 
questionnaires and 
phone calls
t t t t t
Implementation outcomes (organisational capacity)
  Readiness to 
implement
RMT adapted38 t t t
  Fidelity to EPI model FEPS- FS26 t t t
  Fidelity to NAVIGATE Module checklist t t t t
  Staff perceptions of 
value and feasibility*
CFIR adapted39 40 t
  Implementation outcomes (staff capacity)
  Staff knowledge and 
skills
ECHO survey t t t
*Includes perceptions of ECHO support.
CFIR, consolidated framework for implementation research; ECHO, Extension of Community Health Outcomes; EPI, early psychosis intervention; 
FEPS- FS, First Episode Psychosis Services–Fidelity Scale; NIRN, National Implementation Research Network; RMT, readiness monitoring tool.
objECtIvE 2: EvAluAtIon of IndIvIduAl-lEvEl outCoMEs
study procedures
Participant recruitment will be initiated by the clinical team 
at each participating site who will obtain verbal permission 
from potential participants to be contacted by a member of 
the research team. The research team will then meet with 
participants via live two- way videoconference, consistent 
with ECHO infrastructure, to obtain informed consent. 
Participants will read the consent form online and have 
the opportunity to ask the research team questions in real 
time over videoconference. Participants will provide digital 
consent signatures by clicking a checkbox to indicate their 
consent. A copy of the signed consent will be emailed (or 
mailed, if requested) to the participant. A family member of 
each patient will also be invited to participate in the study. 
All interviewer- rated assessments will also be administered 
via two- way live videoconference by trained interviewers, 
in a manner identical to the approach used in the original 
RAISE Trial.21 This method of remote assessment is compa-
rable to in- person assessments for both patient accept-
ability and reliability.45 De- identified study data, including 
interviewer- rated and participant/family member self- 
report assessments, will be entered and managed using 
research electronic data capture tools hosted at CAMH.46 47 
It is anticipated that the first participant will complete the 
study in month 30, while the final participant will complete 
a 2- year follow- up at month 48.
outcome measures
Individual- level outcome measures are outlined in table 3. 
Participants will be administered the Structured Clinical 
Interview for DSM-5 for formal diagnostic assessment,48 
with information supplemented by the clinical team as 
needed. Demographics and a medical history will also be 
recorded at baseline.
Functioning will be assessed with the Heinrichs- Carpenter 
Quality of Life Scale (QLS), administered by semi- 
structured interview.49 The QLS is the most comprehensive 
measure of community functioning in schizophrenia popu-
lations50 and the primary outcome in the RAISE Trial.21 
While the QLS is psychosis- specific, we will measure general 
functioning using the 12- item self- report WHO Disability 
Assessment Schedule 2.0 (WHODAS 2.0),51 consistent with 
DSM-5 recommendations for use across mental illnesses.48 
The interviewer- rated Brief Psychiatric Rating Scale 24- item 
will be used to assess symptom severity52 and the Clinical 
Global Impression Scale will characterise overall illness 
severity and improvement.53Depression symptoms and 
severity will be assessed with the Patient Health Question-
naire-9 (PHQ-9).54 The Adolescent Alcohol and Drug 
Involvement Scale (AADIS) will be administered to char-
acterise current substance use.55 The Service Use and 
Resource Form will be used to measure utilisation of mental 
health and other medical services across residential, inpa-
tient and outpatient treatment settings, with an add- on item 
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Table 3 Participant and family member assessment tools and schedule*
Assessments Construct Who completes
Months from baseline
0 6 12 18 24
Screening
  Demographic form Youth t
  SCID-548 (all modules) Psychopathology Interviewer t
  Medical history Youth t
Functional assessments
  QLS49 Condition- speciic quality of life Interviewer t t t t t
  WHODAS 2.051 (self- administered 
version)
Generic quality of life Youth t t t t t
Clinical assessments
  SCID-548 (mood disorder, psychotic 
disorder, substance use disorder, anxiety 
disorder and obsessive- compulsive and 
related disorder modules)
Psychopathology Interviewer t t
  BPRS52 Psychotic symptoms Interviewer t t t t t
  CGI53 Overall illness severity and 
improvement
Interviewer t t t t t
  PHQ-954 Depression Youth t t t t t
  AADIS55 Substance use Youth t t t t t
Service utilisation
  SURF56 Service utilisation Youth t t t t t
Satisfaction, care quality and therapeutic 
relationship
  OPOC- MHA58 (client version) Satisfaction with services Youth t t t t t
  STAR- P59 Therapeutic relationship Youth t t t t t
  RSA60 Perceptions of recovery principles 
and overall quality of services
Youth t t t t t
Family member- completed assessments
  WHODAS 2.051 (proxy- administered 
version)
Generic quality of life Family member t t t t t
  LSP-2061–63 General functioning Family member t t t t t
  OPOC- MHA58 (caregiver version) Satisfaction with services Family member t t t t t
  S- CGQoL64 Caregiver quality of life Family member t t t t t
*Time indicates months after NAVIGATE initiation for each participant.
.AADIS, Adolescent Alcohol and Drug Involvement Scale; BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impression; LSP-20, Life Skills 
Proile-20; OPOC- MHA, Client Ontario Perception of Care Tool For Mental Health and Addictions; PHQ-9, Patient Health Questionnaire-9; QLS, 
Quality of Life Scale; RSA, Recovery Self- Assessment; S- CGQoL, Schizophrenia Caregiver Quality of Life Questionnaire; SCID-5, Structured Clinical 
Interview for DSM-5; STAR- P, Scale to Assess Therapeutic Relationships—Patient Version; SURF, Service Use and Resource Form; WHODAS 2.0, 
WHO Disability Assessment Schedule 2.0.
to assess medication adherence.56 Most of the patient- level 
assessment tools selected were those used in the original 
RAISE Study, with the exception of the PHQ-9 for depres-
sion (vs the Calgary Depression Scale for Schizophrenia,57 
since Ontario EPI programmes treat affective as well as 
non- affective psychosis), and the addition of the AADIS. 
To measure satisfaction with their care, participants will 
complete the Client Ontario Perception of Care Tool For 
Mental Health and Addictions (OPOC- MHA).58 The Scale 
to Assess Therapeutic Relationships—Patient Version will 
be used to assess participants’ perception of the therapeutic 
relationship with their care team,59 and perspectives on the 
quality of care will be assessed using the participant- rated 
Recovery Self- Assessment Scale.60
To capture the caregiver’s perspective on the participant’s 
functioning, a family member will complete the 12- item 
proxy- administered version of the WHODAS 2.0, as well 
as the Life Skills Profile-20.61–63 Family members will also 
complete the caregiver version of the OPOC- MHA to assess 
their satisfaction with care and the Schizophrenia Caregiver 
Quality of Life Questionnaire64 to assess their quality of life.
statistical analysis
First, we will undertake a pre- post analysis of all of the 
clinical outcome variables. Next, we will compare clinical 
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outcomes common to both EPI- SET and the RAISE Trial 
with the aggregate data from the RAISE Study to assess 
comparability of the intervention in different jurisdictions, 
using a matching- adjusted indirect comparison model.65 
In this approach, we adjust the population receiving the 
intervention to match the average baseline characteris-
tics with a reference population using propensity scores. 
We then compare outcomes across balanced populations. 
This is facilitated by the use of individual patient data (ie, 
individual- level outcome measures as in the RAISE Study) 
and the collection of similar baseline characteristics that 
might influence outcome (eg, age, education, sex, base-
line illness severity, duration of untreated psychosis). As 
with RAISE, the primary outcome of this subproject will 
be the total QLS Score. We will compare our sample with 
the matched RAISE sample on mean or median changes in 
patient- level outcome data. We will also identify subgroups 
of patients with different functional outcome and symptom 
trajectories using latent class growth analysis and latent 
growth mixture modelling.
Overall retention rate at each data point is expected to 
fall within the acceptable range for statistical correction. 
Every effort will be made to prevent dropouts/missing data 
and to complete relevant assessments for participants who 
drop out, including reasons for dropout. As is typical in 
longitudinal research, we anticipate non- random missing 
data. Sensitivity analysis will be conducted to evaluate the 
impact of non- random missing data. We will use a variety 
of software platforms to perform the described analyses 
including the Mplus platform (Muthen and Muthen, 2009–
2016) and the R Project for Statistical Computing. As we 
anticipate missing data both within and across assessments, 
both cross- sectional and longitudinal missing data will be 
handled using best practice procedures including multiple 
imputation and full- information likelihood estimation.
objECtIvE 3: EvAluAtIon of systEM-lEvEl outCoMEs
data sources
The primary data collected for patients receiving NAVI-
GATE in the study sites will be linked deterministically to 
data sources held at ICES via unique OHIP number. Only 
NAVIGATE patients who have consented will have their 
program- level data linked to ICES data. The following ICES 
data sources will be used: the Registered Persons Database, 
which contains information on patient demographics and 
deaths; the OHIP database, which captures data for physi-
cian visits and respective billings66; the Canadian Institute 
for Health Information Discharge Abstract Database, which 
captures all non- psychiatric and non- adult psychiatric 
hospitalisations66 67; the Ontario Mental Health Reporting 
System, which captures adult psychiatric hospitalisations68; 
the National Ambulatory Care Reporting System, which 
captures ED visits and other ambulatory care69 and the 
Ontario Drug Benefits (ODB) claims data, which provides 
information on all outpatient prescriptions covered by ODB 
(based on financial need for those under 65 years of age and 
for young people up to age 25 who lack private insurance). 
These databases can be linked via the encrypted health 
card number such that all the information is available for 
each individual, and de- identified. The health administra-
tive data used for this analysis are collected by the Ministry 
of Health and stored by ICES without patient consent with 
a number of protections in place that have been described 
elsewhere ( www. ices. on. ca). Data will be stored and anal-
ysed onsite at ICES following procedures approved by 
Ontario’s Information and Privacy Commissioner.
study design
This universal administrative data source allows us to 
compare outcomes among study participants and two 
comparison groups: (1) FEP patients in Ontario who have 
received EPI services at non- NAVIGATE sites and (2) FEP 
patients who have not received EPI services. Comparison 
groups will be identified using a validated algorithm that 
detects incident cases of psychotic disorders in the admin-
istrative data.70 We will use propensity score methods to 
ensure comparison populations are similar to NAVIGATE 
participants based on observed characteristics.71 A propen-
sity score is defined as the probability that a person is in 
the ‘exposed’ category. In this case, the exposure condition 
is access to the NAVIGATE protocol. The propensity score 
is developed using logistic regression to model exposure 
to NAVIGATE as a function of observed covariates likely 
to affect the probability of receiving the intervention to 
yield a probability of NAVIGATE access for each subject, 
and therefore creates a scenario whereby individuals who 
do and do not receive NAVIGATE are comparable based 
on measurable variables within the propensity score model. 
The propensity score model will include sociodemographic 
characteristics, clinical factors and prior service use. Indi-
viduals who used EPI services within 5 years preceding the 
index date will be excluded.
outcomes
Our primary outcome is number of psychiatric hospital-
isation days in the year following the index date (NAVI-
GATE baseline). Secondary outcomes will include ED visits, 
suicide attempts, mortality, number of psychiatric hospi-
talisations, time to first psychiatric hospitalisation, visits to 
outpatient psychiatrists and visits to outpatient primary care 
providers, stratified as mental health versus non- mental 
health- related.72–74
Covariates
We will extract information on sociodemographic charac-
teristics, including age, sex, neighbourhood- level income 
quintile and rurality of residence. Clinical covariates will 
include type of diagnosis (schizophrenia, mood disorder 
and so on), source of index diagnosis (hospitalisation, 
outpatient visit) and history of visits with alcohol- related 
or substance- related diagnoses. We will also measure prior 
service use for mental disorders, including the number 
of mental health- related visits to primary care providers, 
psychiatrist visits, mental health- related ED visits and psychi-
atric hospitalisations.
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statistical analysis
Our primary outcome for Objective 3 is number of psychi-
atric hospitalisation days in the year following NAVIGATE 
admission. We will compare the three groups (NAVIGATE, 
non- NAVIGATE EPI users and non- EPI users with FEP) 
across all covariates listed above. We will subsequently 
model total mental health- related hospital days. The regres-
sion model will be determined by the distribution of the 
dependent variables. If normally distributed, we will use 
linear regression; if the distribution assumes a Poisson 
distribution, we will use Poisson regression. Secondary 
outcomes will be modelled using logistic regression (for 
binary outcomes) or Cox proportional hazard modelling 
(for time- to- event outcomes).
Cost analysis
We will employ a costing algorithm available at ICES75 to 
estimate all direct patient- level healthcare costs incurred by 
the public third- party payer (Ontario Ministry of Health) 
across the three comparison groups. This will include costs 
of hospitalisations (both non- psychiatric and psychiatric); 
ED visits; physician services (ie, primary care, psychiatry and 
other) and diagnostic tests; outpatient prescription drugs 
for individuals covered under the ODB programme; home 
care; long- term care and other care. Further details on 
the methodology to calculate cost for each type of health-
care service can be found elsewhere.76 Costs will then be 
compared between groups to ascertain whether there are 
any cost savings associated with NAVIGATE. Furthermore, 
assuming that all subjects will incur healthcare costs, we will 
use a generalised linear model with a gamma distribution 
and a log link to model healthcare costs and determine the 
main cost drivers. Actual model parameters will be deter-
mined by the nature of the cost distributions.
objECtIvE 4: EvAluAtIon of EngAgEMEnt of pEoplE wIth 
lIvEd ExpErIEnCE
Consistent with best practices for youth77–79 and patient80–85 
engagement, opportunities for youth and family partic-
ipation will range from ad hoc, limited commitment (eg, 
surveys or interviews) to full, ongoing participation with 
opportunities for research team membership and mentor-
ship. A youth and family member who previously received 
EPI services at CAMH have collaborated on the project from 
its inception. When the study launched, youth and family 
advisory committees were formally established, comprising 
youth and family members (partners) from each study site. 
These committees meet monthly (via ECHO- style video-
conference or in- person) to guide the research team on 
recruitment strategies, assessment and treatment proto-
cols, outcome measures, interpretation of findings and 
dissemination of the trial learnings to knowledge users. 
A central research coordinator facilitates the meetings. 
Each committee assigns a lead who is also a member of the 
Central Steering Committee where decisions are made, 
and represents the views of their members. Partners are 
oriented to the study, their readiness to join the study team 
is explored, and they receive NAVIGATE training tailored 
to their learning needs. Scientific, clinical and programme 
leaders receive training on how to include patients and 
family members on a team in a meaningful manner. Part-
ners are compensated for their involvement in this study.
Evaluation of youth and family engagement
In collaboration with the Patient Engagement Resource 
Centre,86 we selected the Public and Patient Engagement 
Evaluation Tool87 participant questionnaire for formative 
and summative evaluation of the strength of the partner 
engagement, and the PCORI engagement activity inven-
tory (PECI)88 to capture partners’ contribution to the 
EPI- SET Study. The tools are adapted based on partners’ 
feedback. At baseline, we assess the partners’ intent to 
contribute to the various aspects of the research, and will 
compare this to their reported contribution using the PECI 
at three different times throughout the study. The baseline 
questionnaire also assesses the partners’ and research team 
members’ need for support to achieve authentic engage-
ment, and resources are offered accordingly. Partners’ 
engagement experience with the advisory committee and 
within the Central Steering Committee meetings is assessed 
monthly for formative purposes, and used to correct 
process as required to optimise experience. A summative 
evaluation is conducted at the study end or when a member 
leaves the committee.
pAtIEnt And publIC InvolvEMEnt
Patient involvement of youth and families with lived experi-
ence was informed by current best practices in the research 
literature.77–85 A youth and family member who previously 
received EPI services collaborated on the project from its 
inception, with active participation on the project Steering 
Committee where high- level decisions about the project are 
made. They also lead the Youth Advisory Committee and 
Family Advisory Committee, respectively. These commit-
tees include patients who have received care from the local 
study sites. In monthly meetings in- person and by videocon-
ference as well as over email, the youth and family members 
draw on their past experiences to help guide project deci-
sions. Individual- level assessments completed by youth 
have all been reviewed and selected by the Youth Advisory 
Committee and assessments completed by caregivers by the 
Family Advisory Committee. Study principal investigators 
representing the different project objectives rotate through 
attending the Youth Advisory Committee and Family 
Advisory Committee meetings as another mechanism for 
regular bidirectional communication.
The perspectives of enrolled study participants are 
privileged through the many self- report assessments they 
are asked to complete including measures of their expe-
riences receiving NAVIGATE. Study participants who 
indicate their interest in receiving published materials 
presenting results of the study will provide their email 
address and will be contacted as materials are published. 
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For additional details on patient and public involvement, 
please see Objective 4.
EthICs And dIssEMInAtIon
The study was approved by the Research Ethics Board 
(REB) at Lakeridge Health, Niagara Region Public Health, 
North Bay Regional Health Centre, Health Sciences North 
and the Canadian Mental Health Association Waterloo 
Wellington, in addition to the coordinating centre, the 
Centre for Addiction and Mental Health. The study 
protocol was prepared according to SPIRIT guidelines 
(online supplementary file l).89 REB- approved protocol 
amendments will be posted on  clinicaltrials. gov. The prin-
cipal investigators, scientific committee and study team will 
meet regularly to review accrued data, data confidentiality, 
adherence to protocol design, recruitment and implemen-
tation. During meetings, the scientific committee will also 
review the enrollment of data, the accrual and integrity of 
clinical data, implementation and fidelity of NAVIGATE 
and any adverse event associated with the various compo-
nents of the study.
The results of each of the four study objectives will be 
reported in scientific journal articles and shared with key 
stakeholders as they become available. The study has been 
discussed at regular EPION meetings (of programme 
managers and other representatives) and will be formally 
presented at its bi- annual conference. De- identified partic-
ipant data are available on reasonable request for each 
objective except system- level data held at ICES. A publica-
tions committee will manage access to data. Requests can 
be made by contacting principal investigator Dr. Aristotle 
Voineskos at  aristotle. voineskos@ camh. ca.
ConClusIons
This multisite non- randomised pragmatic hybrid 
effectiveness- implementation type III mixed methods 
study leverages collaboration with multiple stakeholders 
to evaluate implementation of NAVIGATE in diverse EPI 
programmes in Ontario. It is expected that implemen-
tation will lead to improved fidelity to the EPI model, a 
community of practice and model for continuous learning 
for EPI programmes in Ontario, and improvements in 
patient symptoms, functioning and service utilisation (ie, 
diversion from acute mental health treatment including 
hospitalisation days), with meaningful engagement of 
youth and family members in the research process. It is 
anticipated that this research will highlight key ingre-
dients for spread and scale of the NAVIGATE model to 
additional settings with the goal of improving recovery 
for YEAs with psychosis.
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